Navigation
Company
The Company
Leadership
Board of Directors
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Investors & News
IR Overview
Stock
Stock Quote & Chart
Analyst Coverage
Press Releases
Event Calendar
Presentations
Corporate Presentations
Scientific Presentations
Financial
SEC Filings
Financial Reports
Quarterly Results
Forms
Governance
Governance Highlights
Committee Composition
IR Resources
Investor FAQ
Information Request
Email Alerts
IR Contacts
Contact Us
General Contact
For Healthcare Professionals
Careers
ABI-009 (
nab
-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors
Home
ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors
Next Post
Previous Post
ABI-009 (
nab
-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors
April 20, 2019
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
Phase 2 study of
nab
-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas
A Phase 2, open-label, single-arm, prospective, multicenter study of
nab
-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit
Aadi Bioscience to Participate in Upcoming Investor Conferences
nab
-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in
TSC1
and
TSC2
in a Phase 2, Multicenter, Open-label Tumor-Agnostic Trial: PRECISION 1
Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update
Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer
Severe Pulmonary Arterial Hypertension Treated with ABI-009,
nab
-Sirolimus, an mTOR Inhibitor
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.